TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
November 29, 2024 16:25 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
November 27, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
November 25, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
TransCode Therapeutics Open Letter to Shareholders
November 12, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
Open Letter to Shareholders
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
November 05, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Nasdaq Extension to Re-gain Compliance
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
October 23, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review o
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
October 10, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
September 17, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
September 10, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candi-date Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
September 05, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate